the aid library

LIST OPTIONS

Filter

3780

Achieving Health Equity in Contested Areas of Southeast Myanmar

Davis, Bill; Jolliffe, Kim The Asia Foundation (2016) C1

In many of Myanmar’s contested regions, healthcare services are provided through two parallel governance systems – by the government’s Ministry of Health, and by providers linked to ethnic armed organizations. Building upon efforts to build trust between these two actors following ceasefires s... more

Download (440)

View PDF (414)

El control de la Tuberculosis en prisones

A. Bone; A. Aerts, M. Grzemska Organizaición Mundial de la Salud; Comité internacional de la Cruz roja (2000) C_WHO

Manual para directores de programas

Download (423)

View PDF (671)

Facility based integrated management of neonatal and childhood illness (F-IMNCI) - Facilitators Guide (Facility Based Care)

Ministry of Health and Family Welfare Government of India; WHO; UNICEF (2009) C_WHO

External Link

The Role of Communities in Mental Health Care in Low- and Middle-Income Countries: A Meta-Reviewof Components and Competencies

Brandon A. Kohrt,Laura Asher, Anvita Bhardwaj, et al. (2018) CC

Int J Environ Res Public Health. 2018 Jun; 15(6): 1279. Published online 2018 Jun 16. doi: 10.3390/ijerph15061279

Download (137)

View PDF (157)

Strategies and interventions on preventing and responding to violence and injuries among refugees and migrants (2020)

World Health Organization WHO (2020) C_WHO

This technical guidance outlines current evidence, knowledge and best practice relating to incidences of violence and injuries among refugees and migrants in the WHO European Region. It highlights key principles, summarizes priority actions and challenges, maps existing international commitments and... more

Download (150)

View PDF (208)

Recomendações provisórias para o uso da vacina ChAdOx1-S [recombinante] contra COVID-19 (vacina AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™) - Última atualização em 30 de julho de 2021

OPAS, OMS OPAS (2021) CC

Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021

Download (616)

View PDF (704)

A case study of the Essential Health Benefit in Tanzania mainland

Todd G.; Nswilla A.; Kisanga O.; Mamdani M. Regional Network for Equity in Health in east and southern Africa (EQUINET) (2017) C1

Regional Network for Equity in Health in east and southern Africa (EQUINET): Disussion Paper 109
This report describes the evolution of mainland Tanzania’s EHB; the motivations for developing the EHBs, the methods used to develop, define and cost them; how it is being disseminated, communicat... more

Download (85)

View PDF (72)

South Africa - Country Cooperation Strategy 2023 - 2027

World Health Organization WHO (2025) C_WHO

The South African WHO Country Cooperation Strategy (CCS) 2023–2027 focuses on four key strategic priorities based on the country’s health needs and disease epidemiology, while also considering the need for building resilient health systems for UHC and health security in the post pandemic period.... more

Download (223)

View PDF (252)

South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

Download (172)

View PDF (222)

Rapport mondial 2020 : Agissons maintenant - Pour combattre les profondes inégalités et mettre fin aux pandémies
recommended

ONUSIDA (2020) C_WHO

Objectifs 2020 : des avancées disparates. Le rapport de l’ONUSIDA sur l’épidémie mondiale de sida fait état d’un échec accentué par la COVID-19. Depuis 2015, 3,5 millions d’infections au VIH et 820 000 morts supplémentaires liés au sida sont imputables à des objectifs non atteints. ... more

External Link

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Download (1376)

View PDF (1561)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (346)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (505)

View PDF (724)

Interim National Guidelines for Monkeypox Outbreak Response

Federal Ministry of Health - Nigeria Centre for Disease Contro (2017) C2

This document provides information and recommendations for action, based on the current available knowledge around monkeypox. It is a first draft which will be updated in light of evolving evidence and additional information as they become available.